TargetBeta
AR
androgen receptor · also AIS, NR3C4, SMAX1, HUMARA · Nuclear receptor subfamily 3 group C
16 programs in company-led studies act on AR, from 12 companies: 5 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| apalutamiderule | Johnson & Johnson | phase 4 | 3113 running | – | NCIt |
| enzalutamiderule | Astellas Pharma | phase 4 | 6912 running | – | NCIt |
| darolutamiderule | Bayer | phase 4 | 268 running | – | NCIt |
| Clascoteronerule | Cassiopea SpA | phase 4 | 193 running | – | ChEMBL |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 133 running | – | NCIt |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 33 running | BRD4 | a judged reading |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 42 running | NR3C1, PGR | ChEMBL |
| ostarinerule | GTx | phase 3 | 151 running | – | ChEMBL |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 51 running | – | NCIt |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 64 running | – | the company's pipeline |
| luxdegalutamide | Novartis | phase 2 | 33 running | – | the company's pipeline |
| luxdegalutamide | Novartis | phase 2 | 22 running | – | the company's pipeline |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 11 running | – | NCIt |
| Androgen Receptor Degrader GSK5471713 | GlaxoSmithKline | phase 2 | 11 running | – | the company's pipeline |
| TQB3201 | Sino Biopharmaceutical | phase 2 | 11 running | – | the company's pipeline |
| Androgen Receptor Antagonist TQB3720 | Sino Biopharmaceutical | phase 1 | 10 running | – | the company's pipeline |
Conditions their studies are in
- Prostatic Neoplasms, 13 programs
- Prostatic Neoplasms, Castration-Resistant, 4 programs
- Acne Vulgaris, 2 programs
- Breast Neoplasms, 2 programs
- Neoplasm Metastasis, 2 programs
- Neoplasms, 2 programs
- Adenocarcinoma, 1 program
- Alopecia, 1 program
- Bulbo-Spinal Atrophy, X-Linked, 1 program
- Hot Flashes, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026HRS-5041 · Jiangsu HengRui Medicine · phase 2 · NCT06568094
- Dec 1, 2026apalutamide · Johnson & Johnson · phase 4 · NCT03767244
- Dec 3, 2026luxdegalutamide · Novartis · phase 2 · NCT06991556
- Feb 2027Cyproterone Acetate · Eurofarma Laboratorios · phase 3 · NCT06905210
- Mar 2027rezvilutamide · Jiangsu HengRui Medicine · phase 3 · NCT07241416
- Apr 2027TQB3201 · Sino Biopharmaceutical · phase 2 · NCT07172126
- Apr 30, 2027enzalutamide · Astellas Pharma · phase 4 · NCT07783282
- May 25, 2027luxdegalutamide · Novartis · phase 2 · NCT05067140
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.